Brief Article
Copyright ©2012 Baishideng.
World J Gastrointest Oncol. Jun 15, 2012; 4(6): 145-151
Published online Jun 15, 2012. doi: 10.4251/wjgo.v4.i6.145
Table 1 Basic characteristics of study population for the value of serum pyruvate kinase Isoenzyme M2 and carcinoembryonic antigen in colorectal cancer mass screening in Hangzhou, China, 2006-2008 (mean ± SD)
Colorectal lesionnGender
Age (yr)M2-PK (U/mL)CEA (ng/mL)
MaleFemale
Colorectal cancer
Stage I and II55534059.17 ± 10.7113.10 ± 12.075.74 ± 7.49
Stage III3814.75 ± 13.395.68 ± 5.43
Advanced adenoma41251660.17 ± 7.788.58 ± 7.652.68 ± 1.43
Adenoma137686960.34 ± 8.166.70 ± 6.972.58 ± 3.74
Nonadenomatous polyp47252259.04 ± 8.085.13 ± 3.732.55 ± 2.09
IBD71657.43 ± 7.162.51 ± 1.941.71 ± 0.91
Normal1585610257.15 ± 7.962.96 ± 2.171.98 ± 1.02
Table 2 The area under the receiver operating characteristic curve and 95% confidence interval of serum pyruvate kinase isoenzyme M2 in U/mL and carcinoembryonic antigen in ng/mL in diagnosing colorectal lesions in colorectal cancer mass screening in Hangzhou, China, 2006-2008
Colorectal lesionTestAUCSEP-value95% CI
CRC stage I and IICEA0.700.04 < 0.00010.62-0.79
M2-PK0.890.03 < 0.00010.84-0.94
CRC stage IIICEA0.730.05 < 0.00010.63-0.83
M2-PK0.890.03 < 0.00010.84-0.94
Advanced adenomaCEA0.630.050.010.53-0.73
M2-PK0.810.04 < 0.00010.74-0.86
AdenomaCEA0.540.030.280.47-0.60
M2-PK0.690.03 < 0.00010.64-0.76
Nonadenomatous polypCEA0.580.050.090.48-0.68
M2-PK0.690.04 < 0.00010.62-0.78
Inflammatory bowel diseaseCEA0.410.100.400.21-0.61
M2-PK0.420.100.400.21-0.63
Table 3 Diagnostic sensitivity and specificity in percentage at 95% confidence interval of serum M2-pyruvate kinase using various cut-off value settings for different colorectal lesions compared with 158 normal people in colorectal cancer mass screening in Hangzhou, 2006-2008 (95% CI)
M2-PK (U/mL)Colorectal cancer
Advanced adenoma
Adenoma
Non-adenomatous polyp
SensitivitySpecificitySensitivitySpecificitySensitivitySpecificitySensitivitySpecificity
2.00100.00 (100.00-100.00)40.51 (32.85-48.16)95.12 (88.53-100.00)40.51 (32.85-48.16)82.48 (76.12-88.85)40.51 (32.85-48.16)82.98 (72.23-93.72)40.51 (32.85-48.16)
2.5094.62 (90.04-99.21)55.06 (47.31-62.82)85.37 (74.55-96.18)55.06 (47.31-62.82)71.53 (63.98-79.09)55.06 (47.31-62.82)76.60 (64.49-88.70)55.06 (47.31-62.82)
3.0091.40 (85.70-97.10)65.19 (57.76-72.62)75.61 (62.46-88.75)65.19 (57.76-72.62)61.31 (53.16-69.47)65.19 (57.76-72.62)65.96 (52.41-79.50)65.18 (57.76-72.62)
3.5087.10 (80.28-93.91)68.99 (61.78-76.20)73.17 (59.61-86.73)68.99 (61.78-76.20)56.93 (48.64-65.23)68.99 (61.78-76.20)55.32 (41.11-69.53)68.99 (61.78-76.20)
4.0081.72 (73.87-89.58)74.05 (67.22-80.89)65.85 (51.34-80.37)74.05 (67.22-80.89)49.64 (41.26-58.01)74.05 (67.22-80.89)48.94 (34.64-63.23)74.05 (67.22-80.89)
Table 4 Positive predictive value and negative predictive value in percentage at 95% confidence interval of serum M2-pyruvate kinase using various cut-off value settings for different colorectal lesions compared with 158 normal people in colorectal cancer mass screening in Hangzhou, China, 2006-2008 (95% CI)
M2-PK (U/mL)Colorectal cancer
Advanced adenoma
Adenoma
Nonadenomatous polyps
PPVNPVPPVNPVPPVNPVPPVNPV
2.0049.73 (42.57-56.90)100.00 (100.00-100.00)29.32 (21.59-37.06)96.97 (92.83-100.00)54.59 (47.81-61.37)72.73 (63.42-82.03)29.32 (21.59-37.06)88.89 (81.63-96.15)
2.5055.35 (47.62-63.07)94.57 (89.93-99.20)33.02 (24.07-41.97)93.55 (88.56-98.54)57.99 (50.55-65.43)69.05 (60.98-77.12)33.64 (24.69-42.60)88.78 (82.23-95.03)
3.0060.71 (52.62-68.80)92.79 (87.98-97.60)36.05 (25.90-46.19)91.15 (85.91-96.39)60.43 (52.30-68.56)66.03 (58.59-73.46)36.05 (25.90-46.19)86.55 (80.43-92.68)
3.5062.31 (53.98-70.64)90.08 (84.76-95.41)37.97 (27.27-48.68)90.83 (85.67-96.00)61.42 (52.95-69.88)64.88 (57.66-72.10)34.67 (23.90-45.44)83.85 (77.52-90.17)
4.0064.96 (56.31-73.60)87.31 (67.22-80.89)39.71 (28.08-51.34)89.31 (84.02-94.60)62.39 (53.29-71.48)62.90 (55.96-69.85)35.94 (24.18-47.69)82.98 (76.78-89.18)